Genomic Research in Biomedicine Laboratory, Biochemistry and Nutrition Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Parasitology and Bioinformatics Unit, Department of Zoology, Faculty of Science, University of Lagos, Lagos, Nigeria.
Malar J. 2021 Dec 2;20(1):451. doi: 10.1186/s12936-021-03987-6.
The devastating public health impact of malaria has prompted the need for effective interventions. Malaria control gained traction after the introduction of artemisinin-based combination therapy (ACT). However, the emergence of artemisinin (ART) partial resistance in Southeast Asia and emerging reports of delayed parasite sensitivity to ACT in African parasites signal a gradual trend towards treatment failure. Monitoring the prevalence of mutations associated with artemisinin resistance in African populations is necessary to stop resistance in its tracks. Mutations in Plasmodium falciparum genes pfk13, pfcoronin and pfatpase6 have been linked with ART partial resistance.
Findings from published research articles on the prevalence of pfk13, pfcoronin and pfatpase6 polymorphisms in Africa were collated. PubMed, Embase and Google Scholar were searched for relevant articles reporting polymorphisms in these genes across Africa from 2014 to August 2021, for pfk13 and pfcoronin. For pfatpase6, relevant articles between 2003 and August 2021 were retrieved.
Eighty-seven studies passed the inclusion criteria for this analysis and reported 742 single nucleotide polymorphisms in 37,864 P. falciparum isolates from 29 African countries. Five validated-pfk13 partial resistance markers were identified in Africa: R561H in Rwanda and Tanzania, M476I in Tanzania, F446I in Mali, C580Y in Ghana, and P553L in an Angolan isolate. In Tanzania, three (L263E, E431K, S769N) of the four mutations (L263E, E431K, A623E, S769N) in pfatpase6 gene associated with high in vitro IC were reported. pfcoronin polymorphisms were reported in Senegal, Gabon, Ghana, Kenya, and Congo, with P76S being the most prevalent mutation.
This meta-analysis provides an overview of the prevalence and widespread distribution of pfk13, pfcoronin and pfatpase6 mutations in Africa. Understanding the phenotypic consequences of these mutations can provide information on the efficacy status of artemisinin-based treatment of malaria across the continent.
疟疾对公共卫生造成的破坏性影响促使人们需要采取有效的干预措施。青蒿素类复方疗法(ACT)的引入推动了疟疾控制工作的开展。然而,东南亚青蒿素部分耐药性的出现以及非洲寄生虫对 ACT 的寄生虫敏感性延迟的新报告表明,治疗失败的趋势逐渐显现。监测非洲人群中与青蒿素耐药性相关的突变的流行情况对于阻止耐药性的发展至关重要。恶性疟原虫基因 pfk13、pfcoronin 和 pfatpase6 的突变与青蒿素部分耐药性有关。
收集了发表的关于非洲 pfk13、pfcoronin 和 pfatpase6 多态性流行情况的研究文章的结果。在 PubMed、Embase 和 Google Scholar 上检索了 2014 年至 2021 年 8 月期间非洲这些基因多态性的相关文章,pfk13 和 pfcoronin 报道了这些基因的多态性。对于 pfatpase6,检索了 2003 年至 2021 年 8 月期间的相关文章。
87 项研究符合本分析的纳入标准,报告了来自 29 个非洲国家的 37864 株恶性疟原虫分离株中的 742 个单核苷酸多态性。在非洲发现了 5 个经过验证的 pfk13 部分耐药性标记物:卢旺达和坦桑尼亚的 R561H、坦桑尼亚的 M476I、马里的 F446I、加纳的 C580Y 和安哥拉分离株的 P553L。在坦桑尼亚,报告了 pfatpase6 基因中与高体外 IC 相关的四个突变(L263E、E431K、A623E、S769N)中的三个(L263E、E431K、S769N)。在塞内加尔、加蓬、加纳、肯尼亚和刚果报告了 pfcoronin 多态性,其中 P76S 是最常见的突变。
这项荟萃分析提供了非洲 pfk13、pfcoronin 和 pfatpase6 突变的流行情况和广泛分布的概述。了解这些突变的表型后果可以为了解非洲大陆青蒿素类疟疾治疗的疗效状况提供信息。